Skip to search formSkip to main contentSkip to account menu

sibrafiban

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
The initiating event of acute coronary syndromes is atherosclerotic plaque rupture followed by local thrombosis. Antithrombotic… 
Review
2004
Review
2004
Received May 18, 2004; revision received June 21, 2004; accepted August 4, 2004. Remarkable advances in cardiovascular care… 
2002
2002
CAN OBSERVATIONAL DATA SUBSTITUTE FOR RANDOMized controlled trials for developing treatment recommendations and initiating public… 
Review
2001
Review
2001
Secondary prevention of stroke and other manifestations of atherothrombosis is essential if the burden of disease associated with… 
2000
2000
Sibrafiban is a double prodrug that is converted to the inactive single prodrug and to the active GP IIb/IIIa antagonist after… 
1999
1999
Sibrafiban is the orally administered, nonpeptide. double-prodrug of Ro 44-3888 which is a selective glycoprotein IIb/IIIa… 
1999
1999
BACKGROUND Despite progress, atherosclerotic vascular disease remains a major cause of morbidity and mortality. Intravenous… 
1999
1999
Sibrafiban is a double prodrug that is converted to the inactive single prodrug and to the active IIb/IIIa antagonist following…